---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-005122"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2021-12-09T23:59:59+00:00"
generated_at: "2026-06-28T02:22:10.039292+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KalVista reports Q2 net loss $19.7M; advances HAE oral candidates KVD900 and KVD824

## Summary
- Net loss of $19.7M ($0.80 per share) for quarter ended Oct 31, 2021 vs $10.4M ($0.58) year ago.
- Cash, equivalents and marketable securities $209.8M as of Oct 31, 2021; funded into early 2024.
- Preparing to initiate Phase 3 trial for KVD900 (on-demand HAE) in Q1 2022; FDA confirmed trial design.
- Phase 2 KOMPLETE trial for KVD824 (prophylactic HAE) enrolling patients; regulatory approvals in 12 of 13 countries.
- R&D expenses increased to $17.5M from $9.1M due to preclinical, Phase 2 and Phase 3 preparation costs.

## SEC filing metadata
- accession: 0000950170-21-005122
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2021-12-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017021005122/0000950170-21-005122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017021005122/kalv-20211209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-005122
- JSON: https://secwatch.observer/filing/0000950170-21-005122.json
- Plain text: https://secwatch.observer/filing/0000950170-21-005122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.